Premium
Transient trisomy 8 abnormality in Philadelphia‐negative cells during imatinib mesylate treatment of chronic myelogenous leukemia
Author(s) -
KIM M.,
LEE S.,
JUNG C. K.,
LIM J.,
CHO S. G.,
KIM D. W.,
KIM Y.,
HAN K.,
MIN W. S.,
KIM C. C.
Publication year - 2008
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2007.00991.x
Subject(s) - trisomy , chronic myelogenous leukemia , imatinib mesylate , trisomy 8 , medicine , karyotype , leukemia , bone marrow , philadelphia chromosome , imatinib , gastroenterology , pathology , chromosomal translocation , biology , chromosome , genetics , myeloid leukemia , gene
Summary We investigated chronic myelogenous leukemia (CML) patients who developed trisomy 8 abnormalities in Philadelphia‐negative (Ph−) cells during imatinib mesylate treatment to evaluate the clinical outcome and laboratory features. Of the 470 CML patients, 1.5% ( n = 7) developed trisomy 8 chromosomal abnormalities in Ph− cells. The median interval of the first trisomy 8 observation was 12 months. Our follow‐up cytogenetic evaluations revealed that six of the patients demonstrated a complete or partial cytogenetic response and that all of the six patients revealed no dysplastic changes following a bone marrow examination. Moreover, the percentage of trisomy 8 in metaphase karyotyping has decreased in five of the seven subjects. In conclusion, these results suggest that the emergence of trisomy 8 in Ph− cells is transient and not related to therapy‐related myelodysplasia or acute leukemia.